Collection of normal, raw materials, preparation enterprises how to cooperate can maximize profits?

Pharmaceutical network July 28th, with the third batch of national mining began, provincial drug belt collection and comprehensive implementation, drug preparation market varieties, quantities and other market share to achieve "absolute" coverage, the winning enterprise gross profit price space further compressed, the main procurement body by public hospitals, community clinics gradually include retail pharmacies, preparation drug market channels further standardized.pharmaceutical preparation selling enterprises face two major dilemmas: First, whether the winning bid can obtain a reasonable quality and stable supply of raw materials, and second, the winning bid price of preparations decreased year by year, the profit space of enterprises gradually shrinks, in order to survive and develop, the cost elements to raw materials, pharmaceutical package enterprises and other links, seeking low-priced, high-quality raw materials and pharmaceutical supplies supply.some pharmaceutical enterprises such as Shandong Lu anti-medicine, their own production of raw materials and large-scale preparation production capacity, in the pharmaceutical preparation link to optimize the production, and strive to improve the production technology and economic indicators of API, reduce the production costs of RAW materials, with excellent quality, internal low-cost settlement price to support the production of pharmaceutical preparations, for the preparation to participate in national, provincial and municipal drug production of centralized procurement provides a huge cost advantage support.this is a typical model of deep integration within the API and formulation group.profit sharing three modes face drug collection, API and preparation production enterprises in the preparation of the winning price of the "roof", how to co-exist and co-prosperity, as an equal market body, through profit sharing, to achieve the integration and development of the market law truly follow? Specifically, the two sides adopted the profit-sharing model mainly includes: the amount of Poly raw material enterprises, preparation enterprises in product quality, market potential, market profitability, supply capacity on the basis of agreement, through the raw material sinofer supply contract, such as the preparation of high price, large supply, the corresponding API is more sought-after, preparation enterprises need to pay a certain margin, contract, divide the market profit share.this mode, pharmaceutical preparation enterprises have a strong control over the preparation market, can independently bear marketing risks, in the profit sharing occupies a dominant position.market profit-sharing API enterprises at a lower price (small profit per unit of API) supply preparation enterprises, to the agreed preparation market sales profit share ratio, preparation enterprises through a certain financial process, in various forms of cost feedback to the API enterprises.the model can be divided into national market sales profit sharing, designated market sales profit share according to the size of the market.this model is reflected in the risk-sharing of both sides of the market, API enterprises are optimistic about the market prospects, preparation enterprises can save some liquidity for expanding production capacity.intermediary model API enterprises through agents and preparation enterprises to achieve profit sharing, the typical structure is "api-pharmaceutical production enterprises, agents and preparation production enterprises."such as some imported RAW drugs are often through trading companies or independent agents, looking for domestic cooperation in the production of pharmaceutical preparations.the agent with a certain ability to obtain a greater market profit will also obtain the right to use the trademark, through the licensed production method and preparation enterprise cooperation, to achieve the goal of maximizing the sharing of benefits, the typical structure is "the api-pharmaceutical production enterprises , agents , trademark filing licensors , preparation production enterprises."the mode, the agent plays a major role.pharmaceutical preparation enterprises mainly obtain processing fees, low profit share ratio, raw material sources, preparation market control is weak.at present, the preparation of enterprise products of the national agent, provincial agent, regional agent more use of this model.test information grasp the degree on the surface, profit sharing is raw materials, preparation enterprises around the preparation winning price, preparation market to achieve the sales scale of the unit profit, and their respective unit profits after comparison of the demand, its essence is the mutual game of unit costs, to achieve mutual maximization of the transfer process.as the link and integration node of API enterprises and pharmaceutical preparation enterprises, profit sharing is a dynamic and time problem. specialization makes the drug production elements towards independent development, and the integration of the various elements. when the production process of an API matures, from scarcity to popularization, its fate is often by the strength of the preparation enterprises through the expansion of reproduction of the way of integration and absorption; profit sharing is also a reflection of the drug life cycle in the market profit. to the later stage of the life cycle of the drug, the profit-sharing ability of API participating in the pharmaceutical preparation market is gradually decreasing. in fact, the profit-sharing model has a lot to do with whether the market information of api enterprises, preparation enterprises and other partners is equivalent. the availability of raw materials and pharmaceutical products, the resources and market share of the preparation enterprise customers, the pricing price of the preparation drug market, the composition of market share and other information, will affect the way and proportion of profit sharing. api enterprises, preparation enterprises only fully understand the life cycle of cooperative drugs, market situation, market policy, etc., adhering to the concept of win-win cooperation, maximize the use of profit-sharing strategies and tactics, in order to long-term cooperation, access to a larger market. .